CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY
|
|
- Whitney Benson
- 8 years ago
- Views:
Transcription
1 CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004, several important studies in both low-grade and aggressive lymphomas have been published, either in full or at the American Society of Haematology (ASH) meeting in December These revolve in particular around the use of the chimeric human-mouse anti-cd20 monoclonal antibody (rituximab, MabThera). This is a human immunoglobulin antibody with variable regions isolated from a murine anti-cd20 monoclonal antibody. Its use is described in Chapters 12 and 13. It has been studied extensively in vitro and is able to lyse CD-20 positive cells by complement activation or antibody-dependent cell-mediated cytotoxicity. It has other mechanisms of action, which include induction of apoptosis, block of the G1S transition, and an impairment of differentiation. CD-20 is expressed on normal B-cell lymphocytes and in most malignant B-cell lymphomas. It appears essential for the regulation of cell cycle and differentiation. 1 Currently in Australia it is available under the PBS Authority system, where the approved indication is relapsed or refractory low-grade B-cell lymphomas, relapsed or refractory follicular B-cell lymphomas, or untreated CD-positive diffuse large B-cell non-hodgkin s lymphoma in combination with chemotherapy in patients over 60 years of age. The new information that has emerged through the course of 2004 and into 2005 will widen the indications for the use of rituximab in the treatment of lymphomas Low-grade lymphomas new indications for rituximab The German Low-grade Lymphoma Study Group (GLSG) has shown that the addition of rituximab to a combination of fludarabine, cyclophosphamide, and mitozantrone (FCM) significantly increases the response rate and prolongs survival when compared with chemotherapy alone in patients with relapsed and refractory follicular and mantle cell lymphomas. 1 This was a randomised study of some 147 patients. The response rate for R-FCM overall was 79%, including 33% complete remissions as compared with 58% for chemotherapy alone, with 13% complete remissions. The R-FCM arm was significantly superior in terms of progression-free survival and overall survival. There were no differences in clinical relevant side effects in both study arms. However, in a separate study carried out by the same group, the addition of rituximab to CHOP chemotherapy had a long lasting impact on subsequent treatment in remission in follicular lymphoma, but not in mantle cell lymphoma. 2 The GLSG embarked on two parallel studies in follicular lymphoma and mantle cell lymphoma. One was a prospective randomised comparison of R-CHOP versus CHOP alone. This was followed by a second randomisation in remission for interferon maintenance versus myeloablative radio-chemotherapy with subsequent stem cell transplantation in patients under the age 60. All older patients received interferon maintenance. The disease-stage status of these patients is defined in the presentation abstract. In the follicular lymphoma group,the treatment with R-CHOP appeared to have a long-lasting beneficial effect on progression-free survival, which appears to be in the range previously achieved only by chemotherapy followed by peripheral stem cell transplantation. Similarly, a significantly higher response rate and a longer time to disease failure was observed in patients with mantle cell lymphoma. However, no difference was revealed for the progression-free survival after R-CHOP versus CHOP and subsequent therapy with interferon or peripheral blood stem cell transplantation. Therefore, in follicular lymphoma, the addition of rituximab to CHOP has a long-lasting beneficial effect, with a substantial impact on subsequent treatment in remission. In mantle cell lymphoma, the benefit of rituximab appears to be restricted to the remission induction period only. 2 Of greatest Impact of anti-cd20 monoclonal antibodies on lymphoma therapy 417
2 interest, however, are the data suggesting that the addition of rituximab to chemotherapy in previously untreated patients increases event-free survival and response duration. The Roswell Park Cancer Institute has reported a nine-year follow up of patients with low-grade or follicular non-hodgkin s lymphoma (including patients with no prior treatment), treated with rituximab plus CHOP chemotherapy. The overall response rate was 100%, with 87% of patients achieving a complete response. The median times to progression and disease relapse were 82.3 months and 83.5 months respectively. The authors concluded that the rituximab/chop combination provided a lengthy response duration in patients with relapsed or newly diagnosed indolent non- Hodgkin s lymphoma. 3 Similarly, the first analysis of the GELA GOELAMS FL-2000 study of untreated patients with follicular lymphoma was presented at the 2004 ASH meeting. Patients were randomised to a CHOPlike regime containing etoposide in association with interferon, versus a similar arm in which six infusions of rituximab had been added. The first analysis of all patients in this trial demonstrated a significant improvement of response to therapy in the rituximab arm. In the control arm, the eventfree survival at 2.5 years was 62%, versus 78% in the rituximab arm. 4 At ASH 2004, the East German Study Group (Haematology and Oncology) also presented results of a prospective randomised phase III study comparing rituximab plus mitozantrone, chlorambucil and prednisolone chemotherapy (RMCP) versus MCP alone in untreated advanced indolent non- Hodgkin s lymphoma and mantle cell lymphoma. Some 358 patients were randomised. The overall response rate in the RMCP arm was 85.5%, versus 65.5% in the MCP group. Event-free survival (EFS) was significantly prolonged for patients receiving RMCP versus MCP alone. The median EFS for MCP was 19 months, and at this stage the EFS for RMCP was 73%. 5 Similarly, a United States/Canadian group study presented results of a randomised trial of CVP chemotherapy with or without maintenance rituximab in patients with advanced indolent lymphoma. Some 332 stable, responding patients were randomised after chemotherapy to either four cycles of rituximab or observation. Progression-free survival estimates at two and four years from maintenance randomisation were 74% versus 42% and 59% versus 34% for the rituximab and observation arm respectively. The estimated two-year survival from maintenance randomisation was 95% for rituximab and 91% for observation. 6 The Swiss Group for Clinical Cancer Research (SAKK) carried out a randomised trial comparing standard schedule rituximab with a more prolonged treatment in some 200 patients with newly diagnosed or refractory relapsed follicular lymphoma. 7 All patients received standard treatment rituximab 375 mg/m 2 weekly x 4 or were randomised to, in addition, a single 375 mg/m 2 rituximab infusion every two months x 4. Patients with stage I IV disease were included. In 185 evaluable patients, the overall response rate was 67% in chemotherapy naïve patients and 46% in pretreated cases. Patients responding or with stable disease at week 12 were randomised to no further treatment or the prolonged rituximab administration. At a median follow up of 35 months, the medium event-free survival was 12 months in the no-treatment group versus 23 months in the prolonged treatment group. The difference was particularly notable in the chemotherapy naïve patients (19 versus 36 months) and as well in patients responding to induction treatment (16 versus 36 months). It was concluded that in patients with follicular lymphoma, the administration of four additional doses of rituximab at eight-week intervals significantly improved the event-free survival. Richard Fisher presented a review entitled New treatment options have changed the natural history of follicular lymphoma at the 2004 ASH meeting. He showed that trials with chemotherapy followed by monoclonal antibodies have had a significant effect on both progression-free survival and overall survival, thereby changing the natural history of follicular lymphoma Clinical practice guidelines for the diagnosis and management of lymphoma
3 Guideline Low-grade lymphoma aggressive combination chemotherapy Where it is considered appropriate to treat patients with combination chemotherapy, the addition of rituximab increases both complete response rate and duration of response. Level of evidence Refs II Large-cell lymphoma new indications for rituximab At ASH 2004 the GELA Group presented longer-term results of their study of R-CHOP versus CHOP in elderly patients with diffuse large-cell lymphoma. The five-year event-free survival in R-CHOP was 47% versus 29% with CHOP. The five-year overall survival was 58% versus 45%. They concluded that these long-term results continue to show a major benefit for the addition of rituximab to CHOP in the treatment of patients with large B-cell lymphoma (over the age of 60) and that this improvement increases with time. 9 By contrast, Michael Pfreundschuh presented the results of the MinT trial, which was the first analysis of the completed MabThera international trial in young or patients (i.e. less than 60 years) with lowrisk diffuse large B-cell lymphoma. They found that the addition of rituximab to a CHOP-like regime significantly improves outcome of all patients, with the identification of a very favourable subgroup with IPI = 0 and no bulky disease. 10 Guideline Diffuse large-cell lymphoma The outcome of patients, both over and under the age of 60, who are treated with CHOP chemotherapy, is improved by the addition of rituximab. Level of evidence Refs II 9, References 1. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: Hiddemann W, Forstpointner R, Kneba M, et al. The addition of rituximab to combination chemotherapy with CHOP has a long lasting impact on subsequent treatment in remission in follicular lymphoma but not in mantle cell lymphoma: results of two prospective randomized studies of the German Low Grade Lymphoma Study Group American Society of 3. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-hodgkin s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22: Salles G, Foussard C, Mounier N, et al. Rituximab added to aifn+chvp improves the outcome of follicular lymphoma in patients with a high tumor burden: first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients American Society of Impact of anti-cd20 monoclonal antibodies on lymphoma therapy 419
4 5. Herold M, Pasold R, Srock S, et al. Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R- MCP versus MCP alone in untreated advanced indolent non-hodgkin s lymphoma (NHL) and mantle-cell-lymphoma (MCL) American Society of 6. Hochster H, Weller E, and Ryan T. Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL) ASCO. 7. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103: Fisher RI, LeBland M, Press OW, et al. New treatment options have changed the natural history of follicular lymphoma American Society of 9. Coiffier B, Geugler P, Sebban C, et al. Long term results of the GELA study, R-CHOP vs CHOP in elderly patients with diffuse large C-cell lymphoma American Society of 10. Pfreundschuh M, Truemper L, Gill D, et al. First analysis of the completed Mabthera international (MinT) trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL): addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identification of a very favourable subgroup with IPI=O and no bulky disease American Society of 420 Clinical practice guidelines for the diagnosis and management of lymphoma
5 Impact of anti-cd20 monoclonal antibodies on lymphoma therapy 421
Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma
a report by Martin Dreyling Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma Head, Lymphoma Section, Department of Medicine III, University Hospital Großhadern, Ludwig Maximilians-University
More informationDavid Loew, LCL MabThera
MabThera The star continues to rise David Loew, LCL MabThera MabThera the star continues to raise Group sales (CHF bn) 4,5 4,0 3,5 3,0 2,5 2,0 1,5 1,0 0,5 0,0 2001 2002 2003 2004 2005 Outstanding clinical
More informationMonoclonal Antibody Therapy for Lymphoma: Targeting CD20
Monoclonal Antibody Therapy for Lymphoma: Targeting CD20 Session Chair: Jonathan W. Freidberg, MD Speakers: Michele Ghielmini, MD; Jonathan W. Friedberg, MD; and John P. Leonard, MD Multimodality Therapies
More informationGuidelines for the Management of Follicular Lymphoma
Guidelines for the Management of Follicular Lymphoma Scope The following guidance for first- and second-line therapy applies to follicular lymphoma histological grades 1, 2 and 3a according to the World
More informationRituximab in Non - Hodgkins Lymphoma. Fatima Bassa, Dept. of Haematology October 2008
Rituximab in Non - Hodgkins Lymphoma Fatima Bassa, Dept. of Haematology October 2008 World Health Organization lymphoma classification (2001) Peripheral B-cell neoplasms: B-chronic lymphocytic leukemia/small
More informationFDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable
More informationLenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade
More informationNon-Hodgkin s lymphomas (NHLs) are a
Oncology 33 Non-Hodgkin s lymphoma in the elderly The incidence of non-hodgkin s lymphoma (NHL) is increasing, and this increase is even more rapid in the older population. Although treatment of NHL in
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies
More informationEffective for dates of service on or after September 1, 2015, refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm
Effective for dates of service on or after September 1, 2015, refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm Name of Policy: Uses of Monoclonal Antibodies for the Treatment of Non-Hodgkin
More informationAudience Response Question?
Presenter Disclosure Information Session 4: 3:30 PM - 4:15 PM Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management Speaker: Arnold S. Freedman, MD The following relationships
More informationFrequency of NHL Subtypes in Adults
Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults
More informationBendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma Bendamustine with rituximab for the first-line
More informationTreatment of low-grade non-hodgkin lymphoma
Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade
More informationAudience Response Question? Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management. Presenter Disclosure Information
Welcome to Master Class for Oncologists Session 4: 10:00 AM - 10:45 AM Miami, FL December 18, 2009 Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management Speaker: Arnold S. Freedman,
More information1. Introduction. 2. Clinical aspects
1. Introduction MabThera (rituximab) is a genetically engineered chimeric mouse/human monoclonal antibody which binds specifically to the transmembrane antigen, CD20. This antigen is located on pre-b-
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Study Concepts Follicular Lymphomas Mantel Cell Lymphomas Waldenstroem s Disease Key Steps in Improving Treatment for Follicular
More informationAnti-HCV therapy in HCV-related NHL
Gabriele Pozzato M.D. University of Trieste Anti-HCV therapy in HCV-related NHL Questions about HCV+ in NHL Is the NHL related with HCV infection? Which is the best therapeutic strategy? Is the antiviral
More informationRéda Bouabdallah, MD Institut Paoli-Calmettes, Marseille, France. Oran, May, 8th, 2010
FIRST LINE TREATMENT IN FOLLICULAR LYMPHOMA Current Status Réda Bouabdallah, MD Institut Paoli-Calmettes, Marseille, France Oran, May, 8th, 2010 FL is a complex disease One disease, but many profiles 20%
More informationRituximab for the treatment of relapsed or refractory stage III or IV follicular non-hodgkin s lymphoma
DOI: 10.3310/hta13suppl2/06 Health Technology Assessment 2009; Vol. 13: Suppl. 2 Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-hodgkin s lymphoma A Boland, A Bagust,
More informationollicular Lymphoma The following investigations are indicated for most patients with follicular lymphoma:
ollicular Lymphoma Drs. Kevin Imrie & Matthew Cheung Updated August 2007* Fximab Updates: Ritu maintenance therapy Introduction Follicular lymphoma is the second most frequent type of non-hodgkin s lymphoma
More informationEconomic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma
Leukemia & Lymphoma, February 2008; 49(2): 227 236 ORIGINAL ARTICLE: CLINICAL Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma JOHN
More informationMantle Cell Lymphoma Understanding Your Treatment Options
New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department
More informationDIFFUSE LARGE B-CELL LYMPHOMA
DIFFUSE LARGE B-CELL LYMPHOMA Executive Summary Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-hodgkin lymphoma (NHL), constituting up to 40% of all cases globally.[1] This subtype
More informationDiffuse large B-cell lymphoma: the curable disease?
Hematology Meeting Reports 2007; 1(5):77 86 Diffuse large B-cell lymphoma: the curable disease? Michael Pfreundschuh Med Klinik I, Saarland University Medical School, Homburg/Saar, Germany Corresponding
More informationNew Targets and Treatments for Follicular Lymphoma. Disclosures
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Disclosures Consulting fees from:
More informationRituximab for the first-line maintenance treatment of follicular non-hodgkin s lymphoma
Issue date: June 2011 Rituximab for the first-line maintenance treatment of follicular non-hodgkin s lymphoma This guidance was developed using the the single technology appraisal process NICE technology
More informationGuidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre
Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre Background Non-Hodgkin s lymphoma (NHL) makes up approximately 85% of all lymphomas. They are a heterogeneous collection
More informationThe role of chemotherapy in follicular lymphomas Emanuele Zucca, M.D.
The role of chemotherapy in follicular lymphomas Emanuele Zucca, M.D. Oncology Institute of Southern Switzerland (IOSI) Swiss Group for Clinical Cancer Research (SAKK) WHO grading of follicular lymphoma
More informationrituximab 1400mg solution for subcutaneous injection (Mabthera ) SMC No. (975/14) Roche Products Limited
rituximab 1400mg solution for subcutaneous injection (Mabthera ) SMC No. (975/14) Roche Products Limited 06 June 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationAre CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics
Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Disclosure(s) I do not intend to discuss an off-label use
More informationAggressive non-hodgkin s lymphoma long-term survival for all patients?
Hematology Meeting Reports 2007; 1(4):27 41 Aggressive non-hodgkin s lymphoma long-term survival for all patients? Bertrand Coiffier 1 Jacques Tabacof 2 Zhi-Xiang Shen 3 Ulrich Jäger 4 1 Hospices Civils
More informationUNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD
UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharmaceuticals, Inc. Petitioner, v. Biogen Idec, Inc.
More informationJ Clin Oncol 23:8447-8452. 2005 by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 33 NOVEMBER 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma Richard I. Fisher, Michael
More informationTwo Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy
Two Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy Yoichi Kitamura, MD Kazuhiko Hayashi, MD Kazumi Uchida,
More informationGermany; email:mathias.witzens-harig@med.uni-heidelberg.de. Munich, Germany; email: michael.unterhalt@med.uni-muenchen.de
Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial MIR trial Mathias Witzens-Harig 1, Manfred Hensel
More informationChemoimmunotherapy resistant follicular lymphoma A single institutional study
Cancer Research Journal 2014; 2(5): 93-97 Published online September 30, 2014 (http://www.sciencepublishinggroup.com/j/crj) doi: 10.11648/j.crj.20140205.13 ISSN: 2330-8192 (Print); ISSN: 2330-8214 (Online)
More informationHistopathologic results
Self evaluation 1 Clinical Case 55-year-old woman Bilateral enlargement of cervical, axillary and inguinal lymph nodes, largest diameter > 6 cm Hepatosplenomegaly. Enlargement of retroperitoneal, mesenteric
More informationMichael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto
Evolution of Lymphoma Therapy: What can we expect for the rest of the millenium decade? Michael Crump MD Lymphoma Site Leader Princess Margaret Hospital University of Toronto disclaimers Served on advisory
More informationIF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN
+ IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start
More informationAggressive lymphomas. Michael Crump Princess Margaret Hospital
Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:
More informationLauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
More informationRituximab in the Management of Follicular Lymphoma
Hong Kong J Radiol. 2011;14(Suppl):S63-7 REVIEW ARTICLE Rituximab in the Management of Follicular Lymphoma YL Kwong Department of Medicine, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong
More informationRituximab in non-hodgkin Lymphoma (NHL)
Original Article ISSN: 2070-254X Rituximab in non-hodgkin Lymphoma (NHL) Manal Elhabbash MD 1, Abukris Alwindi MD 2 (1) Assistant Professor, Tripoli University, (2) Medical consultant in oncology & hematology
More informationIn the last decade, passive immunotherapy
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Immunotherapy with Rituximab in Follicular Lymphomas Carmen SAGUNA, MD a ; Ileana Delia MUT, MD, PhD a ; Anca Roxana LUPU, MD, PhD a ; Mihaela TEVET,
More informationInduction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL (MCLelderly)
1 von 7 31.07.2012 10:27 Home Search Study Topics Glossary Study 1 of 24 for search of: MCL elderly Previous Study Return to Search Results Next Study Full Text View Tabular View No Study Results Posted
More informationTITLE: Rituximab for Non-Hodgkin s Lymphoma: A Review of the Clinical and Cost- Effectiveness and Guidelines
TITLE: Rituximab for Non-Hodgkin s Lymphoma: A Review of the Clinical and Cost- Effectiveness and Guidelines DATE: 11 January 2010 CONTEXT AND POLICY ISSUES: Non-Hodgkin s lymphoma is the most common hematological
More informationWhat is non-hodgkin lymphoma, how is it treated, and what is the unmet need?
What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? Tim Illidge BSc PhD MRCP FRCR FRCPath Institute of Cancer Sciences, University of Manchester Manchester Cancer Research Centre,
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007
More informationOutline of thesis and future perspectives.
Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy
More informationRituximab Maintenance for 2 Years in Patients with Untreated High Tumor Burden Follicular Lymphoma After Response to Immunochemotherapy
Rituximab Maintenance for 2 Years in Patients with Untreated High Tumor Burden Follicular Lymphoma After Response to Immunochemotherapy G. A. Salles, J. F. Seymour, P. Feugier, F. Offner, A. Lopez-Guillermo,
More informationUpdate on Follicular Lymphoma. Brad Kahl, M.D.
Update on Follicular Lymphoma Brad Kahl, M.D. Follicular Lymphoma: 25% of NHL Cases Other subtypes (9%) T and NK cell (12%) Burkitt (2.5%) Diffuse large B cell (DLBCL) (30%) Mantle cell (6%) Follicular
More informationIntroduction of Rituximab in Front-Line and Salvage Therapies Has Improved Outcome of Advanced-Stage Follicular Lymphoma Patients
2077 Introduction of Rituximab in Front-Line and Salvage Therapies Has Improved Outcome of Advanced-Stage Follicular Lymphoma Patients Stefano Sacchi, MD 1 Samantha Pozzi, MD 1 Luigi Marcheselli, MS 1
More informationImaging, Diagnosis, Prognosis. MinnaTaskinen, 1,2 Marja-Liisa Karjalainen-Lindsberg, 3 Heidi Nyman, 1,2 Leena-Maija Eerola, 1,2 1,2.
Imaging, Diagnosis, Prognosis A HighTumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma PatientsTreated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone
More informationSalvage Chemotherapy with Dexamethasone, Etoposide, Ifosfamide and Cisplatin (DVIP) for Relapsing and Refractory Non-Hodgkin s Lymphoma
IMAJ VOL 11 January 9 Salvage Chemotherapy with Dexamethasone, Etoposide, Ifosfamide and Cisplatin (DVIP) for Relapsing and Refractory Non-Hodgkin s Lymphoma Ariela Dortort Lazar MD 1,, Ofer Shpilberg
More informationDE Tsai 1, HCF Moore 1, CL Hardy 2, DL Porter 1, EY Loh 1, DJ Vaughn 1, S Luger 1, SJ Schuster 1 and EA Stadtmauer 1
Bone Marrow Transplantation, (1999) 24, 521 526 1999 Stockton Press All rights reserved 0268 3369/99 $15.00 http://www.stockton-press.co.uk/bmt Rituximab (anti-cd20 monoclonal antibody) therapy for progressive
More information6/3/2013. Follicular and Other Slow Growing Lymphomas. Stephen Ansell, MD, PhD Mayo Clinic
Follicular and Other Slow Growing Lymphomas Stephen Ansell, MD, PhD Mayo Clinic 1 Learning Objectives Start with an overview of Follicular and other slow growing lymphomas Discuss current and emerging
More informationEffective on or after May 1, 2015,, refer to: Blue Cross and Blue Shield of Alabama Radiation Therapy Management RTM Policies
Effective on or after May 1, 2015,, refer to: Blue Cross and Blue Shield of Alabama Radiation Therapy Management RTM Policies Name of Policy: Radioimmunotherapy in the Treatment of Non-Hodgkin Lymphoma
More informationA 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on
A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on examination. She also has fever, weight loss, and sweats. What
More informationRituximab for the first-line treatment of stage III IV. D Papaioannou,* R Rafia, J Rathbone, M Stevenson, H Buckley Woods and J Stevens
Rituximab for the first-line treatment of stage III IV follicular lymphoma Rituximab for the first-line treatment of stage III IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic
More informationUpdate in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
More informationState-of-the-Art Treatment for Lymphoma December 19, 2007 Guests: David Maloney, M.D., Ph.D Hosted by Andrew Schorr INTRODUCTION
State-of-the-Art Treatment for Lymphoma December 19, 2007 Guests: David Maloney, M.D., Ph.D Hosted by Andrew Schorr Please remember the opinions expressed on Patient Power are not necessarily the views
More informationPerspectives on Recent Non-Hodgkin s Lymphoma (NHL) Data
Perspectives on Recent Non-Hodgkin s Lymphoma (NHL) Data Summary Article James O. Armitage, MD Presented through a strategic collaboration by A series of 5 expert interviews were conducted, focusing on
More informationHematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine
Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells
More informationTreatment of follicular lymphoma
Treatment of follicular lymphoma Mathias J. Rummel Med. Klinik IV/ V - Hämatologie Klinikum der Justus-Liebig Liebig-Universität Gießen MJR Therapy of Follicular Lymphoma wait and see policy alkylating
More informationCAR T cell therapy for lymphomas
CAR T cell therapy for lymphomas Sattva S. Neelapu, MD Associate Professor and Deputy Chair ad interim Department of Lymphoma and Myeloma UT MD Anderson Cancer Center, Houston, TX CAR T cell therapy What
More informationFollicular Lymphoma: Current Management and Future Directions
Treatment decisions and outcomes for patients with follicular lymphoma may be improved with newer diagnostic tests and novel targeted agents. George Van Hook. Barns in Summer. Oil on linen, 22 28. Follicular
More informationRadioimmunotherapy in the Treatment of Non-Hodgkin Lymphoma. Original Policy Date
MP 8.01.28 Radioimmunotherapy in the Treatment of Non-Hodgkin Lymphoma Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013
More informationFollicular lymphoma. What is follicular lymphoma? Freephone helpline 0808 808 5555 information@lymphomas.org.uk www.lymphomas.org.
Freephone helpline 0808 808 5555 information@lymphomas.org.uk www.lymphomas.org.uk is a cancer of the lymphatic system, a type of non-hodgkin lymphoma. Even though more than 12,000 people are diagnosed
More informationRituximab for the treatment of relapsed or refractory stage III or IV follicular non-hodgkin's lymphoma: Review of technology appraisal guidance 37
Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-hodgkin's lymphoma: Review of technology appraisal Issued: February 2008 guidance.nice.org.uk/ta NICE 2008 Contents
More informationLymphoma Diagnosis and Classification
Lymphoma Diagnosis and Classification By Atef Shrit, MD, Pathology B- and T/NK-cell lymphomas are clonal neoplasms of immature and mature B-lymphocytes, T-lymphocytes or natural killer cells at various
More information-Examination of key pipeline candidates with in-depth clinical and commercial profiles of Phase III candidates
Brochure More information from http://www.researchandmarkets.com/reports/1215469/ Pipeline Insight: Lymphomas, Multiple Myeloma & Myelodysplastic Syndromes - Optimization of clinical practice creates opportunities
More informationCure versus control: Which is the best strategy?
Cure versus control: Which is the best strategy? Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY MULTIPLE MYELOMA Cure versus control
More informationGuidelines for the Management of Chronic Lymphocytic Leukaemia (CLL)
Guidelines for the Management of Chronic Lymphocytic Leukaemia (CLL) Version History Version Date Summary of Change/Process 2.0 08.05.08 Endorsed by the Governance Committee 2.1 16.02.11 Circulated at
More informationFollicular Lymphoma. Aruna K. Reddy, MD. Hematology& Oncology Peace Health Southwest Medical Center
Follicular Lymphoma Aruna K. Reddy, MD Hematology& Oncology Peace Health Southwest Medical Center Follicular Lymphoma Malignant neoplasm resulting from clonal proliferation of malignant B-cells Second
More informationTreatment of Follicular Lymphoma
JClin Exp Hematop Vol. 54, No. 1, June 2014 Review Article Treatment of Follicular Lymphoma Koji Izutsu 1,2) Follicular lymphoma (FL) is the most common subtype of indolent lymphomas. Several lines of
More informationAnti-CD20 Antibody Therapy for B-Cell Lymphomas
T h e n e w e ngl a nd j o u r na l o f m e dic i n e clinical therapeutics Anti-CD20 Antibody Therapy for B-Cell Lymphomas David G. Maloney, M.D., Ph.D. This Journal feature begins with a case vignette
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More informationIn non-hodgkin s lymphoma, MabThera is used to treat two types of the disease, both of which affect B-lymphocytes:
EMA/614203/2010 EMEA/H/C/000165 EPAR summary for the public rituximab This is a summary of the European public assessment report (EPAR) for. It explains how the Committee for Medicinal Products for Human
More informationHodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
More informationNon-Hodgkin Lymphoma Richard Orlowski, MD
Non-Hodgkin Lymphoma Richard Orlowski, MD The American Cancer Society (ACS) estimates that 69,740 Americans will be diagnosed with non-hodgkin lymphoma (NHL) in 2013. Excluding non-melanoma skin cancers,
More informationImmunotherapy of Non-Hodgkin s Lymphomas
Immunotherapy of Non-Hodgkin s Lymphomas Oliver W. Press, John P. Leonard, Bertrand Coiffier, Ronald Levy, and John Timmerman Recent years have witnessed the development of a variety of promising immunotherapies
More informationSevere rheumatoid arthritis (a disease that causes inflammation of the joints),where MabThera is given intravenously together with methotrexate.
EMA/614203/2010 EMEA/H/C/000165 EPAR summary for the public rituximab This is a summary of the European public assessment report (EPAR) for. It explains how the Committee for Medicinal Products for Human
More informationIndolent Lymphomas. American Academy of Insurance Medicine 121 st Annual Meeting. Hilton LaJolla October 2012
Indolent Lymphomas American Academy of Insurance Medicine 121 st Annual Meeting Hilton LaJolla October 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC,
More informationGuidelines of the Belgian Hematological Society for newly diagnosed and relapsed follicular lymphoma 2012
2 Guidelines of the Belgian Hematological Society for newly diagnosed and relapsed follicular lymphoma 2012 S. Debussche, A. Van Hoof, A. Sonnet, C. Bonnet, A. Janssens, G. Verhoef, D. Dierickx, V. De
More informationClinical Features, Prognosis and Treatment of Follicular Lymphoma
Clinical Features, Prognosis and Treatment of Follicular Lymphoma Gilles A. Salles Hospices Civils de Lyon; Université Lyon 1, Pierre-Bénite, France Follicular lymphoma constitutes the most frequent indolent
More information亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引
前 言 : 惡 性 淋 巴 瘤 ( 或 簡 稱 淋 巴 癌 ) 乃 由 體 內 淋 巴 系 統 包 括 淋 巴 細 胞 淋 巴 管 淋 巴 腺 及 一 些 淋 巴 器 官 或 組 織 如 脾 臟 胸 腺 及 扁 桃 腺 等 所 長 出 的 惡 性 腫 瘤 依 腫 瘤 病 理 組 織 型 態 的 不 同 可 分 為 何 杰 金 氏 淋 巴 瘤 (Hodgkin s disease) 與 非 何 杰 金
More informationLymphoma Overview Joseph Leach, MD
Lymphoma Overview Joseph Leach, MD 71 year old male presents with complaints of mild fa5gue and a visible mass in the le: supraclavicular region PE demonstrates a firm easily palpable mass in the le: supraclavicular
More informationSupplementary Online Content
Supplementary Online Content Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving
More informationRituximab-Based Chemotherapy and
用 藥 安 全 Drug Safety Rituximab-Based Chemotherapy and Late-Onset Neutropenia Yi-Ling Lu, Wan-Tsui Huang, Chi-Lan Kao, Hsi-Yen Lin Department of Pharmacy, Cathay General Hospital, Taipei, Taiwan Abstract
More informationNetwork Activity and Clinical Audit Report
Managed Clinical Network for Haemato-oncology Network Activity and Clinical Audit Report June 2010 Dr Pam McKay Lead Clinician Heather Wotherspoon Network Manager Table of Contents ACKNOWLEDGEMENTS...
More informationEarly stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy?
Michallet et al. Journal of Hematology & Oncology 2013, 6:45 JOURNAL OF HEMATOLOGY & ONCOLOGY RESEARCH Open Access Early stage follicular lymphoma: what is the clinical impact of the first-line treatment
More informationLymphoma: The Roleof Nurses in the Treatment Process
Lymphoma: The Roleof Nurses in the Treatment Process Sarah Liptrott MSc,BN(Hons), RN Istituto Europeo di Oncologia, Milan (IT) EBMT Swiss Study Day 2014, Zurich, Switzerland LymphomaManagement Watch &
More informationPractice of Interferon Therapy
Interferon Therapy Practice of Interferon Therapy Multiple myeloma and other related hematological malignancies JMAJ 47(1): 32 37, 2004 Akihisa KANAMARU* and Takashi ASHIDA** *Professor, **Lecturer, Department
More informationNATIONAL CANCER DRUG FUND PRIORITISATION SCORES
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated
More information馬 偕 紀 念 醫 院 新 竹 分 院 淋 巴 癌 放 射 治 療 指 引
馬 偕 紀 念 醫 院 新 竹 分 院 淋 巴 癌 放 射 治 療 指 引 2010.05.12 新 增 2013.06.03 四 版 前 言 新 竹 馬 偕 醫 院 放 射 腫 瘤 科 藉 由 跨 院 聯 合 會 議 機 制 進 行 討 論, 以 制 定 符 合 現 狀 之 淋 巴 癌 放 射 治 療 指 引 本 院 淋 巴 癌 放 射 治 療 指 引 的 建 立, 係 參 考 國 內 外 文 獻
More informationFollicular Lymphoma. 1. Introduction. 2. Diagnosis. 3. Baseline Investigations
Follicular Lymphoma Follicular Lymphoma Treatment policy prepared by Dr. Louise Bordeleau 1. Introduction Follicular lymphoma is the second most frequent type of non-hodgkin s lymphoma. These lymphomas
More informationPhase II Trial of R -C H O P V s C H O P C hem otherapy in Pakistani D iffuse Large B cell Lym phom a Patients
Original Article Phase II Trial R -C H O P V s C H O P C hem otherapy in Pakistani D iffuse Large B cell Lym phom a Patients Objective: To determine response and relapse rates in diffuse large B cell lymphoma
More informationIntroduction CLINICAL TRIALS AND OBSERVATIONS
CLINICAL TRIALS AND OBSERVATIONS Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-hodgkin lymphoma in patients both with and without rituximab during induction: results
More informationCycle frequency: Every four weeks Total number of cycles: 6-8
Fludarabine Low Grade non-hodgkin s Lymphoma and CLL Fludarabine 25mg/m 2 oral Days 1-5 Cycle frequency: Every four weeks Total number of cycles: 6-8 Anti-emetic group Low Prophylactic co-trimoxazole and
More information